CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 211 enrolled
Drug / intervention
Nasal Fluticasone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02180672
NCT02180672Phase 3Completed

Utility of Nasal Steroids for Treatment of Childhood Obstructive Sleep Apnea

Children's Hospital of Philadelphia·interventional·Posted Jul 3, 2014·Updated Nov 10, 2021

In Brief

A Phase 3 clinical trial evaluating Nasal Fluticasone and Placebo for Obstructive Sleep Apnea Syndrome. Completed, enrolled 211 participants across 1 site.

Detailed Summary

This double-blind, randomized controlled trial will evaluate the use of nasal corticosteroids for the treatment of the childhood obstructive sleep apnea syndrome (OSAS). Efficacy, duration of action and side-effects will be determined.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 3, 2014
Enrollment StartSep 1, 2014
Primary CompletionDec 30, 2019
Study CompletionOct 30, 2021
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 12.0 years ago

Interventions

Nasal Fluticasonedrug

One spray per nostril, per day.

Placebodrug

One spray per nostril, per day.